share_log

瑞信:维持阿里健康(00241)“跑赢大市”评级 目标价降26.7%至11港元

Credit Suisse: maintain Alibaba Health Information Technology's (00241) "outperform" rating target price down 26.7% to HK $11

智通財經 ·  Nov 29, 2021 11:00

Credit Suisse released a research report that maintained Alibaba Health Information Technology's 00241 "outperform" rating, with a lower-than-expected net loss in the first half, cut revenue growth and gross profit margin, and lowered the target price from HK $15 to HK $11, Zhitong Financial APP learned.

According to the report, the management directs that revenue will grow by about 30% in the 2022-24 fiscal year, and gross revenue will be stable and profitable. Exploration of new businesses, such as proprietary pharmacies and personalized insurance, is under way. The bank does not expect to launch an online prescription drug sales policy this year, but the policy could affect revenue growth by several percentage points.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment